News

Caretaker Medical Awarded the Grand Prize in NIH RADx Tech for Maternal Health Challenge

Caretaker Medical, a digital health company focused on developing hemodynamic monitoring devices, today announced that it has been awarded the $525,000 grand prize in the US National Institutes of Health (NIH) Rapid Acceleration of Diagnostics Technology for Maternal Health Challenge. The award recognizes Caretaker’s wireless, wearable wrist device, VitalStream, that can be used to monitor postpartum women for episodes of hyper- or hypotension, as well as detect the early onset of hemorrhage and sepsis. VitalStream continuously measures heart rate, blood pressure, respiration, cardiac output and stroke volume, among other vital signs.

In the US, over 80% of pregnancy-related deaths are preventable. And in 2020, 36% of deaths occurred 1-42 days postpartum. Continuous monitoring can help clinicians detect clinical decompensation sooner. A noninvasive, wireless monitor can expand advanced monitoring capabilities to more women and can potentially even be worn after hospital discharge.

“We are honored to receive this award and to be recognized for VitalStream’s potential to impact maternal health outcomes,” stated Jeff Pompeo, President and CEO of Caretaker Medical. “VitalStream can offer clinicians the continuous data they need to intervene earlier, potentially save the lives of new mothers.”

The RADx challenge prioritized technologies that are innovative, easy to use and can be used to help reduce health disparities.

For more information or to schedule a demonstration, contact Caretaker Medical.

Read more here.

Recent News

10/17/2025

BRAINBox Solutions Announces Publication in JAMA Network OPEN of Major Analysis of Initial HeadSmart II Trial Concussion Patients

BRAINBox Solutions today announced the publication in JAMA Network OPEN of a major analysis of the first 1,000 patients with suspected concussion (mild traumatic brain injury or mTBI) in its pivotal, HeadSMART II study of its initial test, BRAINBox TBI, for concussion diagnosis and prognosis. The analysis, the largest of its kind, identified patient characteristics

10/16/2025

Phlow Corp. Selected by the U.S. Food and Drug Administration Commissioner’s First-Ever National Priority Voucher Pilot Program to Advance Manufacturing of a Critical Essential Medicine in America

Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), today announced that the active pharmaceutical ingredient for ketamine will be included in the first-ever U.S. Food and Drug Administration (FDA) Commissioner’s National Priority Voucher (CNPV) Pilot Program. This designation recognizes Phlow’s leadership in advancing domestic manufacturing of essential and life-changing medicines

10/16/2025

Civica To Launch Long-Acting Insulin Glargine in the US in January 2026

Non-profit pharmaceutical company Civica will launch an affordable long-acting insulin – insulin glargine-yfgn in pre-filled pens – at the lowest list price in the current long-acting insulin market. Civica insulin glargine will be available in the United States beginning January 1, 2026. In California, the product will carry the “CalRx” brand. “Civica will provide insulin